Document and Entity Information - USD ($) |
12 Months Ended | ||
|---|---|---|---|
Sep. 30, 2026 |
Nov. 06, 2026 |
Mar. 31, 2026 |
|
| Cover [Abstract] | |||
| Document Type | 10-K | ||
| Amendment Flag | false | ||
| Document Period End Date | Sep. 30, 2026 | ||
| Document Fiscal Year Focus | 2026 | ||
| Document Fiscal Period Focus | FY | ||
| Trading Symbol | ENTA | ||
| Entity Registrant Name | ENANTA PHARMACEUTICALS, INC | ||
| Entity Central Index Key | 0001177648 | ||
| Current Fiscal Year End Date | --09-30 | ||
| Entity Well-known Seasoned Issuer | No | ||
| Entity Current Reporting Status | Yes | ||
| Entity Voluntary Filers | No | ||
| Entity Interactive Data Current | Yes | ||
| Entity Filer Category | Non-accelerated Filer | ||
| Entity Small Business | true | ||
| Entity Emerging Growth Company | false | ||
| Entity Shell Company | false | ||
| ICFR Auditor Attestation Flag | false | ||
| Document Financial Statement Error Correction [Flag] | false | ||
| Entity Common Stock, Shares Outstanding | 29,158,815 | ||
| Entity Public Float | $ 264,303,817 | ||
| Title of 12(b) Security | Common Stock, par value $0.01 per share | ||
| Security Exchange Name | NASDAQ | ||
| Entity File Number | 001-35839 | ||
| Entity Incorporation, State or Country Code | DE | ||
| Entity Tax Identification Number | 04-3205099 | ||
| Entity Address, Address Line One | 4 Kingsbury Avenue | ||
| Entity Address, City or Town | Watertown | ||
| Entity Address, State or Province | MA | ||
| Entity Address, Postal Zip Code | 02472 | ||
| City Area Code | 617 | ||
| Local Phone Number | 607-0800 | ||
| Document Annual Report | true | ||
| Document Transition Report | false | ||
| Documents Incorporated by Reference | Information for Part III of this Form 10-K will either (i) be incorporated by reference to portions of the registrant’s Definitive Proxy Statement for its 2027 Annual Meeting of Stockholders, or (ii) if the Definitive Proxy is not filed with the Securities and Exchange Commission within 120 days after the registrant’s fiscal year end of September 30, 2026, it will be provided by amendment to this Form 10-K. | ||
| Auditor Name | PricewaterhouseCoopers LLP | ||
| Auditor Location | Boston, Massachusetts | ||
| Auditor Firm ID | 238 | ||
| Auditor Opinion | Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of Enanta Pharmaceuticals, Inc. and its subsidiary (the "Company") as of September 30, 2026 and 2025, and the related consolidated statements of operations, of comprehensive loss, of stockholders’ equity and of cash flows for each of the three years in the period ended September 30, 2026, including the related notes (collectively referred to as the "consolidated financial statements"). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of September 30, 2026 and 2025, and the results of its operations and its cash flows for each of the three years in the period ended September 30, 2026 in conformity with accounting principles generally accepted in the United States of America. |